DEFA14A 1 zk1415216.htm DEFA 14A zk1415216.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the Securities
Exchange Act of 1934 (Amendment No.         )
Filed by the Registrant þ
Filed by a Party other than the Registrant o
 
Check the appropriate box:
 
o
Preliminary Proxy Statement
o
Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)(2))
o
Definitive Proxy Statement
þ
Definitive Additional Materials
o
Soliciting Material Pursuant to Rule 14a-12
   
INTEGRITY APPLICATIONS, INC.
(Name of Registrant as Specified in Its Charter)
 
N/A
(Name of Person(s) Filing Proxy Statement, if Other than the Registrant)
Payment of Filing Fee (check the appropriate box):

þ
No fee required
o
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
 
1)
Title of each class of securities to which transaction applies:
 
2)
Aggregate number of securities to which transaction applies:
 
3)
Per unit price of other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
 
4)
Proposed maximum aggregate value of transaction:
 
5)
Total fee paid:
o
Fee paid previously with preliminary materials.
o
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing:
 
1)
Amount Previously Paid:
 
2)
Form, Schedule or Registration Statement No.:
 
3)
Filing Party:
 
4)
Date Filed:
 
 
 
 
 
Integrity Applications, Inc. Announces Adjournment of Annual Meeting

ASHKELON, Israel – July 9, 2014 -- Integrity Applications, Inc. (OTCQB: IGAP) (the "Company" or "Integrity"), developer of the GlucoTrack model DF-F noninvasive blood glucose measurement device, announced today that its annual meeting of stockholders scheduled for, and convened on July 8, 2014, was adjourned due to the lack of requisite quorum.  Only stockholders of record on the record date, May 20, 2014, are entitled to and are being requested to vote.

The annual meeting has been adjourned to July 22, 2014 at 4:00 p.m. Israel time (9:00 a.m. Eastern Daylight Time) at 102 Ha’Avoda St., Ashkelon, Israel, to allow additional time for the stockholders to vote on the proposals set forth in the Company’s proxy statement filed with the SEC, which is available at http://www.sec.gov/Archives/edgar/data/1506983/000117891314001485/zk1414817.htm.

During the period of the adjournment, the Company will continue to solicit proxies from its stockholders with respect to the proposals set forth in the Company’s proxy statement.  Proxies previously submitted in respect of the meeting will be voted at the adjourned meeting unless properly revoked. Stockholders who would like to vote directly at the meeting can obtain a ballot by contacting the Company by telephone: 972-(8)- 675-7878 or sending an email to eranh@integrity-app.com.

The Company encourages all stockholders who have not yet voted to do so before July 21, 2014 at 11.59 p.m. (Eastern Daylight Time). The stockholders may vote by internet at www.voteproxy.com, or by telephone at 1-800-776-9437 in the United States or 1-718-921-8500 from foreign countries and follow the instructions, or in person by attending the adjourned Annual Meeting.

Except as previously disclosed, no changes have been made in the proposals to be voted on by stockholders at the annual meeting.  The Company’s proxy statement and any other materials filed by the Company with the SEC remain unchanged and can be obtained free of charge at the SEC’s website at www.sec.gov and at http://www.astproxyportal.com/ast/16881/.
 
About GlucoTrack
 
GlucoTrack features a small sensor that clips to the earlobe and measures the wearer’s blood glucose level by taking measurements using three technologies. The measurements are analyzed using a proprietary algorithm and displayed on a small handheld device, the size of a mobile phone. The derived blood glucose measurement is also announced verbally, making it suitable for the elderly and vision-impaired diabetes patients. The company has obtained a CE Mark for its GlucoTrack Model DF-F in Europe (June 2013) and intends to seek Food and Drug Administration approval for GlucoTrack in the United States.
 
About Integrity Applications, Inc.
 
Integrity Applications, Inc. is a medical device company focused on the design, development and commercialization of non-invasive glucose monitoring devices for use by people with diabetes. Integrity Applications has developed the GlucoTrack model DF-F non-invasive glucose monitoring device, which is designed to help people with diabetes obtain blood glucose level measurements without the pain, inconvenience, incremental cost and difficulty or discomfort of conventional (invasive) spot finger stick devices. Integrity Applications works primarily through its wholly-owned Israeli subsidiary, A.D. Integrity Applications, Ltd. For more information please visit www.integrity-app.com.
 
Contact:
 
Integrity Applications
Eran Hertz, +972 (8) 675-7878 ext. #3
CFO
eranh@integrity-app.com